The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 424)
Research Grant, 2018
There is a pressing need for Parkinson's disease (PD) biomarkers -- objective measures of disease -- that will enable early and accurate diagnosis and allow to track disease progression and therapeutic improvement. We have developed a new mathematical method to characterize PD-related brain networks. This method is based on a mathematical analysis of data collected via resting sta...
Research Grant, 2017
Improving Participation in Clinical Trials in Individuals with Atypical Parkinsonian Syndromes through Virtual Research Visits (ImPaCT-Atypical)
The Michael J. Fox Foundation's Fox Trial Finder is designed to facilitate and increase the participation of individuals with Parkinson's disease (PD) and degenerative parkinsonian syndromes in clinical trials and studies. Distance, disability and the distribution of movement disorder specialists and research centers limits participation of individuals with PD and other degene...
Therapeutic Pipeline Program, 2017
Parkinson's disease (PD) involves accumulation of toxic proteins in cells in specific areas of the brain. These cells normally have protective mechanisms to remove these toxic proteins and dysfunction of these mechanisms may play a role in the development of PD. A major goal of this grant is to explore novel ways to allow these cells to restore their ability to remove these toxic ...
Researchers: Stephanos Ioannidis, PhD
Research Grant, 2017
Evidence suggests that increased activity of the c-abl protein in the brain may contribute to the development and progression of Parkinson's disease (PD). Nilotinib, a drug that inhibits c-abl, has recently shown promise as a potential therapeutic. In its activated state, c-abl is modified with a phosphate group (protein regulator) and measuring the extent of phosphorylation may b...
Researchers: David R. Walt, PhD
Target Validation Award, 2017
Although the precise mechanism(s) for neurodegeneration in Parkinson's disease (PD) is unknown, evidence suggests that neuroinflammation is an important contributor. In this study, we will use pre-clinical models of PD to determine whether existing drugs targeting the farnesoid x receptor, protein that regulates metabolism, can reduce inflammation and protect dopamine neurons.
Researchers: Jason R. Richardson, PhD, MS, DABT